4-[chloro(pyridin-3-yl)methyl]benzonitrile | 745750-95-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[chloro(pyridin-3-yl)methyl]benzonitrile
• 英文别名: 4-[alpha-chloro(3'-pyridyl)methyl]benzonitrile
• CAS: 745750-95-2
• 化学式: C₁₃H₉ClN₂
• 分子量: 228.681
• InChiKey: NACLGAPKEDTTIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-[chloro(pyridin-3-yl)methyl]benzonitrile 在 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 potassium iodide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 60.0h， 生成 4-{[4-(4-methyl-1,3-thiazole-5-carbonyl)piperazin-1-yl](pyridin-3-yl)methyl}benzonitrile
  参考文献：
  名称：

  Design, structure–activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi

  摘要：

  A scaffold hopping exercise undertaken to expand the structural diversity of the fenarimol series of anti-Trypanosoma cruzi (T. cruzi) compounds led to preparation of simple 1-[phenyl(pyridin-3-yl)methyl]piperazinyl. analogues of fenarimol which were investigated for their ability to inhibit T. cruzi in vitro in a whole organism assay. A range of compounds bearing amide, sulfonamide, carbamate/carbonate and aryl moieties exhibited low nM activities and two analogues were further studied for in vivo efficacy in a mouse model of T. cruzi infection. One compound, the citrate salt of 37, was efficacious in a mouse model of acute T. cruzi infection after once daily oral dosing at 20, 50 and 100 mg/kg for 5 days. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.050
• 作为产物：
  描述：

  4-碘氰基苯 在 氯化亚砜 、 异丙基氯化镁 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 1.42h， 生成 4-[chloro(pyridin-3-yl)methyl]benzonitrile
  参考文献：
  名称：

  Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease

  摘要：

  Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is an increasing threat to global health. Available medicines were introduced over 40 years ago, have undesirable side effects, and give equivocal results of cure in the chronic stage of the disease. We report the development of two compounds, 6 and (S)-7, with PCR-confirmed curative activity in a mouse model of established T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7. Compounds 6 and (S)-7 have potent in vitro activity, are noncytotoxic, show no adverse effects in vivo following repeat dosing, are prepared by a short synthetic route, and have druglike properties suitable for preclinical development.

  DOI：

  10.1021/jm401610c

文献信息

• Alpha-heterocyclc substituted tolunitriles
  申请人：Ciba-Geigy Corporation

  公开号：US04978672A1

  公开（公告）日：1990-12-18

  The invention is concerned with aromatase inhibiting compounds of formula I ##STR1## wherein R and Ro represent hydrogen or lower alkyl; or R and Ro located on adjacent carbon atoms and together when combined with the benzene ring to which they are attached form a naphthalene or tetrahydronaphthalene ring; R.sub.1 and R.sub.2 independently represent hydrogen, lower alkyl, (lower alkyl, aryl or aryl-lower alkyl)-thio, lower alkenyl, aryl, aryl-lower alkyl, C.sub.3 -C.sub.6 -cycloalkyl, or C.sub.3 -C.sub.6 -cycloalkyl-lower alkyl; or R.sub.1 and R.sub.2 combined represent lower alkylidene, mono- or di-aryl-lower alkylidene; R.sub.1 and R.sub.2 combined also represent C.sub.4 -C.sub.6 -straight chain alkylene, lower alkyl-substituted straight chain alkylene or ortho-phenylene bridged-C.sub.2 -C.sub.4 -straight chain alkylene, each forming with the carbon atom attached thereto a corresponding optionally substituted or benzo-fused 5, 6 or 7-membered ring; W represents 1-imidazolyl, 1-(1,2,4- or 1,3,4)-triazolyl or 3-pyridyl; or W represents 1-imidazolyl, 1-(1,2,4 or 1,3,4)-triazolyl or 3-pyridyl substituted by lower alkyl; and pharmaceutically acceptable salts thereof.

  该发明涉及式I的芳香化酶抑制化合物##STR1##其中R和Ro代表氢或较低的烷基；或R和Ro位于相邻的碳原子上，当与它们连接的苯环结合时形成萘或四氢萘环；R.sub.1和R.sub.2独立地代表氢、较低的烷基、(较低的烷基、芳基或芳基-较低的烷基)-硫、较低的烯基、芳基、芳基-较低的烷基、C.sub.3-C.sub.6-环烷基或C.sub.3-C.sub.6-环烷基-较低的烷基；或R.sub.1和R.sub.2结合代表较低的烷基亚甲基、单芳基或双芳基-较低的烷基亚甲基；R.sub.1和R.sub.2结合还代表C.sub.4-C.sub.6-直链烷基、较低的烷基取代的直链烷基或邻苯二甲基桥联的C.sub.2-C.sub.4-直链烷基，每个与其连接的碳原子形成相应的可选择取代或苯并5、6或7-成员环；W代表1-咪唑基、1-(1,2,4-或1,3,4)-三唑基或3-吡啶基；或W代表1-咪唑基、1-(1,2,4或1,3,4)-三唑基或3-吡啶基，其被较低的烷基取代；以及其药学上可接受的盐。
• US4978672A
  申请人：——

  公开号：US4978672A

  公开（公告）日：1990-12-18
• US5112845A
  申请人：——

  公开号：US5112845A

  公开（公告）日：1992-05-12
• US5352795A
  申请人：——

  公开号：US5352795A

  公开（公告）日：1994-10-04
• US5473078A
  申请人：——

  公开号：US5473078A

  公开（公告）日：1995-12-05